866-997-4948 (US-Canada Toll Free)

Asthma Therapeutics Market to 2019 - Breakthrough Biologics to Enhance Treatment of Severe Asthma and Drive Market Growth

Published By :

GBI Research

Published Date : 2013-10-09

Category :

Therapeutic Area

No. of Pages : N/A

Product Synopsis

GBI Research, a leading business intelligence provider, has released its latest research report “Asthma Market to 2019”. The asthma market is forecast to grow marginally over the forecast period across the leading eight developed nations, from $16.6 billion in 2012 to a projected value of $21.6 billion in 2019. This growth is expected despite the generic erosion facing the leading brands, and is a consequence of new market entrants and a disease prevalence that continues to rise, albeit not at rates as high as have been seen in the past. Some new, costly asthma therapies could be set to enter the asthma market, including GlaxoSmithKline’s (GSK’s) recently approved Relvar (fluticasone/vilanterol), and multiple monoclonal antibodies (mAbs). ... Read More

Table Of Content

Table of Content

1 Table of Contents
1.1 List of Tables
1.2 List of Figures

2 Introduction
2.1 Disease Introduction
2.2 Symptoms
2.3 Etiology
2.4 Pathophysiology
2.5 Diagnosis
2.6 Assessment of Disease Severity
2.7 Treatment
2.8 Treatment Algorithm

3 Marketed Products
3.1 Product Profiles
3.1.1 Advair Diskus (fluticasone and salmeterol) – GlaxoSmithKline
3.1.2 Symbicort (budesonide/formoterol) – AstraZeneca, Co-promotion with Astellas Pharma Inc
3.1.3 Singulair (montelukast) – Merck & Co
3.1.4 Xolair (omalizumab) – Novartis and Genentech
3.1.5 Foradil (formoterol) – Novartis (Co-marketed by Novartis and Schering Corporation)
3.1.6 Dulera/Zenhale (mometasone/formoterol) – Merck & Co
3.1.7 Relvar/Breo – GlaxoSmithKline/Theravance

4 Asthma Pipeline
4.1 Overview
4.2 Mechanisms of Action in the Pipeline
4.3 Clinical Trials
4.3.1 Failure Rate
4.3.2 Clinical Trial Duration
4.3.3 Clinical Trial Size
4.3.4 Comparative Clinical Trial Metrics Analysis
4.4 Promising Pipeline Molecules
4.4.1 Reslizumab – Teva Pharmaceutical ltd
4.4.2 Mepolizumab - GlaxoSmithKline
4.4.3 Lebrikizumab – Roche/Genentech
4.4.4 Veramyst - GlaxoSmithKline
4.4.5 Andolast – Rottapharm Madaus
4.4.6 Spiriva (Tiotropium Bromide) – Boehringer Ingelheim
4.5 Heat Map of Safety and Efficacy for Pipeline and Marketed Products

5 Market Forecast to 2019
5.1 Geographical Markets
5.1.1 Global Market
5.1.2 North America
5.1.3 Top Five Countries of Europe
5.1.4 Japan
5.2 Drivers and Barriers for the Asthma Therapeutics Market
5.2.1 Drivers
5.2.2 Barriers

6 Strategic Consolidations
6.1 Major Licensing Deals
6.2 Major Co-development Deals

7 Appendix
7.1 All Pipeline Drugs by Phase
7.1.1 Discovery
7.1.2 Preclinical
7.1.3 Phase I
7.1.4 Phase II
7.1.5 Phase III
7.1.6 Filed
7.1.7 Undisclosed
7.2 Market Forecast to 2019
7.2.1 Global
7.2.2 US
7.2.3 Canada
7.2.4 UK
7.2.5 France
7.2.6 Germany
7.2.7 Italy
7.2.8 Spain
7.2.9 Japan
7.3 References
7.3.1 References for Pipeline Heat Map
7.3.2 References for Marketed Heat Map
7.4 Market Definitions
7.5 Abbreviations
7.6 Methodology
7.7 Coverage
7.8 Secondary Research
7.9 Therapeutic Landscape
7.10 Epidemiology-Based Forecasting
7.10.1 Analogous Forecasting Methodology
7.11 Market Size by Geography
7.11.1 Forecasting Model for Therapeutic Areas
7.12 Geographical Landscape
7.13 Pipeline Analysis
7.14 Competitive Landscape
7.14.1 Expert Panel Validation
7.15 Contact Us
7.16 Disclaimer

List of Tables


Table 1: Asthma Therapeutics Market, Global, Classification of Asthma Severity in Children of 0–4 Years of Age
Table 2: Asthma Therapeutics Market, Global, Classification of Asthma Severity in Children of 5–11 Years of Age
Table 3: Asthma Therapeutics Market, Global, Classification of Asthma Severity in Youths = 12 Years of Age and Adults
Table 4: Management of Chronic Asthma
Table 5: Management of Acute Asthma
Table 6: Asthma Therapeutics Market, Global, Pipeline, Discovery, 2013
Table 7: Asthma Therapeutics Market, Global, Pipeline, Preclinical, 2013
Table 8: Asthma Therapeutics Market, Global, Pipeline, Phase I, 2013
Table 9: Asthma Therapeutics Market, Global, Pipeline, Phase II, 2013
Table 10: Asthma Therapeutics Market, Global, Pipeline, Phase III, 2013
Table 11: Asthma Therapeutics Market, Global, Pipeline, Filed, 2013
Table 12: Asthma Therapeutics Market, Global, Pipeline, Undisclosed, 2013
Table 13: Asthma, Global, Market Forecast, 2012–2019
Table 14: Asthma, US, Market Forecast, 2012–2019
Table 15: Asthma, Canada, Market Forecast, 2012–2019
Table 16: Asthma, UK, Market Forecast, 2012–2019
Table 17: Asthma, France, Market Forecast, 2012–2019
Table 18: Asthma, Germany, Market Forecast, 2012–2019
Table 19: Asthma, Italy, Market Forecast, 2012–2019
Table 20: Asthma, Spain, Market Forecast, 2012–2019
Table 21: Asthma, Japan, Market Forecast, 2012–2019

List of Figures


Figure 1: Asthma Therapeutics Market, Global, Pipeline, 2013
Figure 2: Asthma Therapeutics Market, Global, Pipeline by Mechanism of Action, 2013
Figure 3: Asthma Therapeutics Market, Global, Pipeline by Mechanism of Action, Phase I, 2013
Figure 4: Asthma Therapeutics Market, Global, Pipeline by Mechanism of Action, Phase II, 2013
Figure 5: Asthma Therapeutics Market, Global, Pipeline by Mechanism of Action, Phase III, 2013
Figure 6: Asthma Therapeutics Market, Global, Clinical Trial Failure Rate, 2013
Figure 7: Asthma Therapeutics Market, Global, Clinical Trial Failure Rates by Mechanism of Action, Phase I, 2013
Figure 8: Asthma Therapeutics Market, Global, Clinical Trial Failure Rates by Mechanism of Action, Phase II, 2013
Figure 9: Asthma Therapeutics Market, Global, Clinical Trial Failure Rates by Mechanism of Action, Phase III, 2013
Figure 10: Asthma Therapeutics Market, Global, Pipeline, Clinical Trial Duration, 2013
Figure 11: Asthma Therapeutics Market, Global, Pipeline, Clinical Trial Duration by Mechanism, Phase I, 2013
Figure 12: Asthma Therapeutics Market, Global, Pipeline, Clinical Trial Duration by Mechanism, Phase II, 2013
Figure 13: Asthma Therapeutics Market, Global, Pipeline, Clinical Trial Duration by Mechanism, Phase III, 2013
Figure 14: Asthma Therapeutics Market, Global, Pipeline, Clinical Trial Size, 2013
Figure 15: Asthma Therapeutics Market, Global, Pipeline, Clinical Trial Size by Mechanism, Phase I, 2013
Figure 16: Asthma Therapeutics Market, Global, Pipeline, Clinical Trial Size by Mechanism, Phase II, 2013
Figure 17: Asthma Therapeutics Market, Global, Pipeline, Clinical Trial Size by Mechanism, Phase III, 2013
Figure 18: Asthma Therapeutics Market, Global, Pipeline, Mechanism of Action Heat Map, 2012
Figure 19: Asthma Therapeutics Market, Global, Reslizumab Forecast ($m), 2014–2019
Figure 20: Asthma Therapeutics Market, Global, Mepolizumab Forecast ($m), 2015–2019
Figure 21: Asthma Therapeutics Market, Global, Lebrikizumab Forecast ($m), 2015–2019
Figure 22: Asthma Therapeutics Market, Global, Veramyst Forecast ($m), 2014–2019
Figure 23: Asthma Therapeutics Market, Global, Andolast Forecast ($m), 2015–2019
Figure 24: Asthma Therapeutics Market, Global, Tiotropium Bromide Forecast ($m), 2014–2019
Figure 25: Asthma Therapeutics Market, Global, Pipeline, Efficacy Heat Map, 2013
Figure 26: Asthma Therapeutics Market, Global, Pipeline, Safety Heat Map, 2013
Figure 27: Asthma Therapeutics Market, Global, Marketed Products, Safety and Efficacy Heat Map, 2013
Figure 28: Asthma Therapeutics Market, Global, Pipeline, Competitor Grid, 2013
Figure 29: Asthma Therapeutics Market, Global, Treatment Patterns, 2012–2019
Figure 30: Asthma Therapeutics Market, Global, Market Size, 2012–2019
Figure 31: Asthma Therapeutics Market, North America, Treatment Patterns, 2012–2019
Figure 32: Asthma Therapeutics Market, North America, Annual Cost of Treatment, 2012–2019
Figure 33: Asthma Therapeutics Market, North America, Market Size, 2012–2019
Figure 34: Asthma Therapeutics Market, Top Five EU Countries, Treatment Patterns, 2012–2019
Figure 35: Asthma Therapeutics Market, Top Five EU Countries, Annual Cost of Treatment, 2012–2019
Figure 36: Asthma Therapeutics Market, Top Five EU Countries, Market Size ($bn), 2012–2019
Figure 37: Asthma Therapeutics Market, Japan, Treatment Patterns and Annual Cost of Treatment, 2012–2019
Figure 38: Asthma Therapeutics Market, Japan, Market Size, 2012–2019
Figure 39: Asthma Therapeutics Market, Global, Major Licensing Deals, 2006–2013
Figure 40: Asthma Therapeutics Market, Global, Major Licensing Deals, 2006–2013
Figure 41: Asthma Therapeutics Market, Global, Major Licensing Deals, 2006–2013
Figure 42: Asthma Therapeutics Market, Global, Major Licensing Deals, Completed and Terminated
Figure 43: Asthma Therapeutics Market, Global, Major Licensing Deals by Phase and Molecule Type, 2006–2012
Figure 44: Asthma Therapeutics Market, Global, Major Licensing Deals, Mechanism of Action
Figure 45: Asthma Therapeutics Market, Global, Major Co-developments by Region and Value, 2006–2013
Figure 46: Asthma Therapeutics Market, Global, Major Co-developments by Year, 2006–2013
Figure 47: Asthma Therapeutics Market, Global, Major Co-developments by Phase, 2006–2013
Figure 48: Asthma Therapeutics Market, Global, Major Co-developments by Phase and Molecule Type, 2006–2013
Figure 49: Forecasting Model for Therapeutic Areas

Make an enquiry before buying this Report

Please fill the enquiry form below.

Full Name * Message
Your Email *
Job Title
Phone No. * (Pls. Affix Country Code) Security Code *

Upcoming Reports

  • Under Ground Mining Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2013 - 2019

    By - Transparency

    The mining industry finds itself in a new era due to global economic and political trends. Strengthening demand for primary resources predominately from emerging economies has taken up the mining industry to a new level. Underground mining allows coal extracting companies to explore and extract deeper coal reserves and is viewed as less destructive than strip mining. In pillar and room mines coal columns are left to support the ground during the initial stage of mining, later they are also extracted and the mine is left for collapsing and this process is called subsidence. In long wall...

  • Greece: market of plastic sacks and bags

    By - Williams and Marshal Strategy

    This report presents a comprehensive overview of the plastic sacks and bags market in Greece and its state as of January 2014. It provides detailed analysis of the industry, its dynamics and structure. The purpose of the report is to describe the state of the plastic sacks and bags market in Greece, to present actual and retrospective information about the volumes and dynamics of production, imports, exports and consumption, the characteristics of the market for the period 2008-2012 and to build a forecast for the market development until 2018. In the same way, the report presents an...

  • High Temperature Plastics Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019

    By - Transparency

    Plastic materials are required to sustain specified service conditions at their application base. Usually, if a plastic is capable of sustaining the service temperature above 150°C; it is industrially termed as high temperature plastic. These materials are dimensionally stable and show excellent mechanical properties over wide range of temperature. Those mechanical properties include resistance to wear, abrasion and hardness etc. Some other properties are good electrical insulation characteristics, resistance to UV, resistance to fire and chemical resistance. These materials require...